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Abstract
Strong evidence indicates oxidative stress in the pathogen-
esis of Alzheimer’s disease (AD). Amyloid b (Ab) has been
implicated in both oxidative stress mechanisms and in
neuronal apoptosis. Glutaredoxin-1 (GRX1) and thioredoxin-1
(TRX1) are antioxidants that can inhibit apoptosis signal-
regulating kinase (ASK1). We examined levels of GRX1 and
TRX1 in AD brain as well as their effects on Ab neurotoxicity.
We show an increase in GRX1 and a decrease in neuronal
TRX1 in AD brains. Using SH-SY5Y cells, we demonstrate
that Ab causes an oxidation of both GRX1 and TRX1, and
nuclear export of Daxx, a protein downstream of ASK1. Ab
toxicity was inhibited by insulin-like growth factor-I (IGF-I) and
by overexpressing GRX1 or TRX1. Thus, Ab neurotoxicity
might be mediated by oxidation of GRX1 or TRX1 and
subsequent activation of the ASK1 cascade. Deregulation of
GRX1 and TRX1 antioxidant systems could be important
events in AD pathogenesis.
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Introduction
Alzheimer’s disease (AD) is characterized by several neuro-
pathological changes, including accumulation of intracellular
neurofibrillary tangles and extracellular plaques, as well as
vast synaptic and neuronal loss. The main constituent of AD
plaques is the 39–43 amino-acid long, amyloid b (Ab) peptide.
Ab deposition has been proposed as the major pathogenic
event that drives AD pathology.1 The precise mechanisms
leading to Ab neurotoxicity are not fully understood, but
several evidences, from both in vitro and in vivo studies,
suggest that oxidative stress plays a key role (for review,
see Huang et al. 2). Ab has been shown to induce apoptosis
in several paradigms,3 and signs of activation of apoptosis
have been shown in both transgenic models of AD and in
postmortem AD brain samples,4,5 supporting the idea that the
progressive cell loss seen in AD involves apoptosis. Gluta-
redoxins (GRX) and thioredoxins (TRX) are endogenous
antioxidant systems and key players in the balance of cellular
redox homeostasis. Two glutaredoxin genes (GRX) have
been found in mammals, GRX1 and GRX2.6 GRX1 encodes
GRX1, a protein that resides mainly in the cytoplasm although
it can translocate into the nucleus upon certain stimuli. GRX2
encodes two isoforms, a mitochondrial and a nuclear GRX2.
When oxidized, the GRX isoforms are regenerated by
reduced glutathione (GSH). The resulting oxidized glutathione
(GSSG) is in turn reduced by glutathione reductase at the
expense of NADPH. These molecules form the glutaredoxin
system in which GRX1 plays a prevalent role (Figure 1a).6 At
least two TRX isoforms have been characterized in mammals,
cytosolic (TRX1) and mitochondrial (TRX2), of which TRX1 is
the major redox protein. TRX is reduced by TRX reductase
(TRXR) via NADPH. The TRX system is completed by a
TRX peroxidase that is reduced by TRX and additionally
scavenges reactive oxidative species (Figure 1b).6
In addition to their role in oxidative stress, GRX1 and TRX1
have been shown to regulate apoptosis through the apop-
tosis signal-regulating kinase-1 (ASK1) cascade. ASK1 is a
mitogen-activated protein kinase kinase kinase (MAPKKK)
that is bound to the reduced state of either GRX1 or TRX1.
When GRX1 or TRX1 are oxidized, ASK1 is liberated and can
initiate the MAPK cascade leading to activation of c-Jun
N-terminal kinase (JNK) or p38,7,8 as well as to the transloca-
tion of death-associated protein (Daxx) from the nucleus to
the cytosol.9 The exogenous administration or overexpres-
sion of GRX1 or TRX1 is protective against apoptosis, as
shown in several studies.10,11 Whether this is achieved
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through an inhibition of the ASK1 cascade or through other
ASK1-independent mechanisms is not yet clear.
Recently, it was suggested that ASK1 activation is a key
mechanism in Ab neurotoxicity,12 but if this activation is
GRX1/TRX1 dependent remains to be explored. The role
of GRX1 and TRX1 in AD is largely unknown, but a few
reports over recent years, albeit conflicting, suggest a
possible involvement of these proteins in protection from AD
oxidative stress. In an mRNA expression profiling study of
AD hippocampal CA1 neurons, GRX1 was found to be
downregulated in tangle-bearing neurons compared to normal
neurons in AD brains.13 Protein levels of TRX1 have also been
found to be decreased in AD brain in areas associated with AD
pathology.11 In contrast, Asahina et al.14 showed that, in AD
brain, TRX1 staining was increased in astrocytes in the white
matter, and suggested that this reflects the need for increased
antioxidant protection.
The present study aims to provide insight into the role
of GRX1 and TRX1 in Ab toxicity and AD. We first inves-
tigated the expression of GRX1 and TRX1 in AD brain. Then,
using human neuroblastoma SH-SY5Y cells, we analyzed
the effects of Ab on the redox states of GRX1 and TRX1,
and on other antioxidant systems, specifically catalase and
glutathione. Finally, we investigated the possible involve-
ment of the ASK1 cascade in Ab-mediated apoptosis
and the possible protective effects of GRX1 and TRX1
overexpression.
Results
GRX1 and TRX1 expressions in AD brain
Figure 2 shows immunohistochemical studies of GRX1
(Figure 2a) and TRX1 (Figure 2b) expressions in frontal
cortex and hippocampal CA1 regions of AD brains and age-
matched controls. Both brain regions are widely affected in
AD. The number of neurons and its staining intensity were
estimated using a stereological semiquantitative approach.
The results are summarized in Table 1. We found that GRX1
expression was increased in neurons of AD brains (Table 1,
Figure 2a). In contrast, TRX1 expression was reduced
(Table 1, Figure 2b). Similar results were found in slices from
hippocampal dentate gyrus (data not shown).
In controls, GRX1 was localized mostly in the cytosolic
compartment (Figures 2a and 3a) and was particularly visible
in layer II, III and V pyramidal neurons. Generally, for control
brains, cortical pyramidal neurons showed more immuno-
reactivity than hippocampal pyramidal cells. In AD brains,
hippocampal neurons showed in general more immunoreac-
tivity than cortical neurons. In AD brains, healthy neurons as
determined according to Oppenheimer’s criteria, including
the central position of the nucleus and the presence of a
single large conspicuous nucleolus,15 displayed intensive
GRX1 cytoplasmic positivity even in dendritic compartments
(Figures 2a, 3b and d). This was in contrast to neurons
with morphological features indicating neurodegeneration
Figure 1 Glutaredoxin (a) and thioredoxin (b) systems
Figure 2 Expression of GRX1 and TRX1 in AD brains. (a) Immunostaining of
GRX1 and (b) TRX1 in frontal cortex and hippocampal CA1 regions from one AD
brain (female, 80 years old) and one control brain (female, 83 years old). GRX1
expression was increased, while TRX1 expression decreased in neurons of AD
brains. In AD brains, an occasional increase in immunoreactivity was found in
astrocyte-like profiles for TRX1 (asterisk) in all regions analyzed. Similar
expression patterns were seen in the other brains studied
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(changes in the body shape, deformation and shifting of the
nucleus to the periphery or disappearance of nucleolus),
especially in hippocampal areas where a specific form of
pyramidal cell degeneration (granulovacuolar degeneration)
was visible (Figure 3e).
TRX1 immunoreactivity was also mainly present in the
cytosol, with no differences in intensity between brain regions.
TRX1 was greatly decreased in AD brains compared with
controls (Figure 2b). Additionally, we found occasional
positively stained astrocyte-like profiles in AD brains (asterisk
in Figure 2b). Hematoxylin was used as a background staining
(blue). As seen in Figure 2, no differences were seen in
hematoxylin staining in all the sections.
GRX1 is only expressed in neurons, while TRX1 is
expressed in both neurons and glial cells. In addition, both
neuronal loss and increased gliosis are characteristic features
of AD brains.16 Taking these facts in account, we further
analyzed the expression of GRX1 and TRX1 in AD and control
brains by immunoblotting. Indeed, we saw a decrease in
neuronal synaptophysin and an increase in glial fibrillary
acidic protein (GFAP) in AD brains (Figure 4) as indicators of
neuronal loss and enhanced gliosis, respectively. As shown
in Figure 4, no major differences were seen in GRX1 and
TRX1 immunoreactivity in homogenates from AD and control
brains. These results together with those seen in immunohis-
tochemistry (Table 1 and Figure 2) indicate that the reduced
number of neurons present in AD brains express more GRX1.
In addition, an increased number of glial cells in AD brains
masks the differences seen in neuronal TRX1 when brain
homogenates are analyzed.
Ab oxidizes GRX1 and TRX1 in a rapid, transient
manner
GRX1 and TRX1 are redox active proteins that can have
several different redox states, varying from fully reduced to
fully oxidized, depending on the surrounding cellular environ-
ment. To analyze the effects of Ab on GRX1 and TRX1 redox
states, we exposed human SH-SY5Y cells for 1, 5 and 24 h to
full-length Ab(1–42) (10 mM), the shorter Ab(25–35) (10mM)
and the reverse and non-toxic form Ab(35–25) (10 mM).
Figure 5 shows the separation between the different redox
states after incubation of the samples with AMS (4-acetamido-
Figure 3 GRX1 immunoreactivity is increased in healthy neurons in AD.
Staining of individual neurons with the anti-GRX1 antibody in hippocampus,
dentate gyrus from control (a) and AD (b) brains and in CA1 region from control
(c) and AD (d, e) brains. The neurons with high immunoreactivity of GRX1 in AD
brains (b, d) showed a normal morphology (shape, central nucleus, single
nucleolus). In contrast, signs of neurodegeneration such as displaced nucleus
and granulovacuolar degeneration were found in AD brain neurons with low
GRX1 expression (e). Bar¼ 10 mm
Figure 4 Immunoblotting of brain GRX1 and TRX1. Immunoblots of temporal
cortex homogenates from control and AD cases using antibodies against GRX1,
TRX1, the neuronal marker synaptophysin, the glial marker GFAP and actin. No
differences were found in GRX1 and TRX1 expression between AD and control
brain homogenates. As expected, synaptophysin levels were reduced and GFAP
increased in AD reflecting neuronal loss and gliosis




Total cells/mm2 98 000710700 64 00078700
Heavily stained cells (%) 4 93.7
Low or nonstained cells (%) 96 6.2
Hippocampus (CA1)
Total cells/mm2 115715 110717
Heavily stained cells (%) 3.4 85
Low or nonstained cells (%) 96.6 15
Anti-TRX1
Frontal cortex
Total cells/mm2 98 000710700 64 00078700
Heavily stained cells (%) 86 11.7
Low or nonstained cells (%) 14 88.3
Hippocampus (CA1)
Total cells/mm2 115715 110717
Heavily stained cells (%) 84.3 54
Low or nonstained cells (%) 15.7 46
Quantification of GRX1- and TRX1-positive neurons. Total number of cells is
presented7SD. Number of stained cells is given as percentage of total number
of cells
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40-maleimidyl-stilbene-2,20-disulfonate) and subsequent gel
electrophoresis. As determined using reducing (dithiothreitol
(DTT), 10 mM) or oxidizing (H2O2, 1 mM) conditions, the
upper band is the fully reduced and the lower the fully oxidized
redox state (Figure 5).
As shown in Figure 5, Ab(1–42) (10 mM) induced an early
and transient oxidation of both GRX1 and TRX1, seen at 1 and
5 h, but not at 24 h. Ab(25–35) (10mM) effects were very
mild and also transient, being seen only at 5 h treatment. In
contrast, the reverse peptide Ab(35–25) (10 mM) did not
induce any significant effect.
Effects of Ab(1–42) on catalase and glutathione
antioxidant systems
We next analyzed the effects of Ab(1–42) on two other major
cellular antioxidant systems, namely catalase and glutathione
by measuring catalase activity and levels of GSH. Catalase
is an antioxidant enzyme involved in the degradation and
detoxification of H2O2 and glutathione is the main redox buffer
in the cell. SH-SY5Y cells were treated for 1, 5 and 24 h with
Ab(1–42) (10 mM). Ab(1–42) significantly increased catalase
activity after 5 and 24 h (Figure 6a). Ab(1–42) decreased GSH
levels at 24 h with no effect at earlier time points (Figure 6b).
Ab(1–42) induces apoptosis and Daxx
translocation in SH-SY5Y cells
GRX1 and TRX1 have been shown to be regulators of the
apoptosis cascade mediated by ASK1. When reduced, GRX1
and TRX1 are bound to ASK1, thereby inhibiting its activity.
In contrast, when they are oxidized ASK1 is free to initiate
apoptosis. Ab(1–42) has been shown to induce apoptosis in
several in vitro models. Since we showed that Ab(1–42)
caused an early oxidation of both GRX1 and TRX1, we next
analyzed the effects of Ab(1–42) on apoptosis and the
possible involvement of the ASK1 apoptotic cascade in the
Ab(1–42)-mediated cytotoxicity. We first studied effects on
cell viability using the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-
2H-tetrazolium bromide (MTT)-reduction assay. Ab(1–42)
(10 mM) inhibited MTT reduction by approximately 30% at
2 h and by 40% at 5 and 24 h. This effect was significant with
time (Po0,001; ANOVA), (see Figure 7a for comparisons
at each time point). Ab(1–42) (10mM) gave increased levels
of apoptosis in a time-dependent manner (Po0.001; ANO-
VA), with approximately 300 and 600% increases in mono-
and oligo-nucleosome levels after 5 and 24 h treatment,
respectively, as compared to nontreated cells (Figure 7b).
To investigate the involvement of the ASK1 cascade in the
Ab(1–42)-induced apoptosis, we analyzed the Ab(1–42)
effects on Daxx translocation from the nuclei to the cytosol.
Daxx is a downstream protein in the ASK1 cascade.
Activation of ASK1 induces Daxx phosphorylation and its
translocation to the cytosolic compartment by a JNK-
mediated mechanism.9 Figure 8a and c shows Daxx
immunoblots of cytosolic and nuclear fractions of cells treated
with Ab(1–42) (10 mM) for 2 and 24 h. A treatment with H2O2
(1 mM, 20 min) was also used as a positive control for the
experiment. Quantitative analysis of the blots with data
expressed as ratios of nuclear Daxx to total amount of
Daxx showed that the Ab(1–42)-induced translocation was
statistically significant already after 2 h treatment (Figure 8b).
Figure 6 Effects of Ab(142) on (a) catalase activity and on (b) GSH levels.
Cells were treated for 1, 5 or 24 h with 10 mM Ab(1–42). Untreated cells were
used as controls (C). Data are mean7S.E.M. of six experiments expressed as
ratio of values for untreated control cells. Statistical analysis of the results was
carried out using ANOVA followed by Fisher’s PLSD post hoc test. *Po0.05
Figure 5 Effects of Ab on the redox states of GRX1 and TRX1. GRX1 and
TRX1 immunoblots of lysates from cells treated with 10 mM of Ab(1–42), Ab(25–
35) or the reverse Ab(35–25) for 1, 5 and 24 h, as well as untreated cells (C).
AMS was added to the samples to separate the different redox forms. To confirm
the specificity of each band, reducing (DTT; 10 mM, 2 h) and oxidizing (H2O2;
1 mM, 2 h) treatments were used. Three independent experiments gave similar
results
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To ensure the loading of gels and purity of the fractions, the
same membranes were stripped and reblotted for the nuclear-
specific protein Lamin A (nuclear fractions and cytosolic
fractions) and actin (cytosolic fractions) (Figure 8a and c).
Ab(1–42) effects on Daxx relocalization were further
analyzed with immunocytochemistry. As shown in Figure 8d,
10 mM Ab(1–42) induces translocation of Daxx from the
nucleus to the cytosol at both 5 and 24 h. A treatment with
H2O2 (1 mM, 20 min) was used as a positive control for the
experiment.
IGF-I protects against Ab toxicity in a PI3K-
independent manner
IGF-I has been shown to protect against Ab toxicity in several
cellular paradigms.17,18 This protection has been shown to
involve both activation of extracellular signal-regulated kinase
(ERK) and phosphatidylinositol 3-kinase (PI3K) signaling
pathways.18 IGF-I has also been shown to inhibit ASK1
activity and therefore apoptosis, by a mechanism that
is independent of its effects on the PI3K antiapoptotic
cascade.17 We next analyzed the protective effects of IGF-I
against Ab(1–42) toxicity when ERK or PI3K antiapoptotic
pathways were inhibited. For this, we coincubated cells with
IGF-I (20 nM) and Ab(1–42) (10 mM) with and without the
specific inhibitors LY294002 (50mM; for PI3K) and U0126
(5mM; for MEK, an upstream kinase of ERK) and then
analyzed cell viability using the MTT assay.
The inhibitors were used in a 30 min pretreatment and
during the coincubations with Ab(1–42) and IGF-I. The
efficiency of the inhibitors was previously checked by
immunoblotting extracts of treated cells with anti-phospho-
Akt (a downstream serine/threonine kinase that is phosphory-
lated by PI3K) and anti-phospho-ERK antibodies. These
Figure 7 Ab(142) reduces cell viability and induces apoptosis in SH-SY5Y
cells. (a) Effects of 10 mM Ab(1–42) on MTT reduction. Cells were treated for 1, 2,
5, 10 or 24 h. Four experiments were performed in triplicate. (b) Effects of 10 mM
Ab(1–42) on apoptosis. Cells were treated for 1, 5 or 24 h. Three experiments
were performed in triplicate. Data (mean7S.E.M.) are expressed as percentage
of values in untreated cells (*Po0.05; ***Po0.001; ANOVA followed by Fisher’s
PLSD post hoc test)
Figure 8 Ab(1–42) induces Daxx translocation in SH-SY5Y cells. Immunoblots
of cytosolic and nuclear fractions of cells treated with Ab(1–42) (10 mM) for (a) 2 h
and (c) 24 h using anti-Daxx, anti-Lamin and anti-actin antibodies. Untreated
cells were used as controls (C). A treatment with H2O2 (1 mM) for 20 min was
used as a positive control. (b) Quantification of the Ab(1–42) effects on Daxx
translocation at 2 h. Histogram shows the mean7S.E.M of values from four
independent experiments with data expressed as ratio of nuclear Daxx to total
Daxx. Significant differences were determined using Student’s t-test. *Po0.05.
(d) Micrographs of SH-SY5Y cells that were untreated (Control), treated with
1 mM H2O2 for 20 min or with 10 mM Ab(1–42) for 5 and 24 h and then stained for
Daxx. In untreated cells, Daxx immunofluorescence was concentrated mainly in
the nuclei. Both Ab(1–42) and H2O2 treatments induced translocation of Daxx
and immunofluorescence was seen in the cytosolic projections of SH-SY5Y cells.
Arrows indicate some examples
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antibodies recognize active forms of Akt and ERK. LY294002
(50mM) and U0126 (5 mM) strongly inhibited Akt and ERK
phosphorylation, respectively, at both 2 and 5 h (Figure 9a),
without changing total expression levels of these proteins as
demonstrated by immunoblotting with anti-Akt and anti-ERK
antibodies (data not shown).
To analyze the putative effects of IGF-I against Ab(1–42)
toxicity, we selected a 5 h treatment, since at this time point we
previously showed that Ab(1–42) induces apoptosis. As
shown in Figure 9b, IGF-I (20 nM) fully protected SH-SY5Y
cells against Ab(1–42) toxicity (Po0.001). When PI3K was
blocked by LY294002 (50 mM), IGF-I was still protective
(Po0.001). However, PI3K inhibition slightly decreased the
IGF-I protection (Po0.05 against both controls and IGF-I
treated cells) (Figure 9b). When ERK was blocked by U0126
(5 mM), IGF-I did not protect against Ab(1–42) toxicity
(Figure 9b). IGF-I/Ab(1–42) cotreatment with simultaneous
inhibition of both PI3K and ERK was more toxic than Ab(1–42)
alone (P40.01).
Overexpression of GRX1 or TRX1 protects cells
from Ab toxicity
The effects of overexpression of GRX1 or TRX1 on Ab(1–42)
toxicity in SH-SY5Y cells were evaluated by studying cell
viability with the MTT assay. SH-SY5Y cells were transiently
transfected with either GRX1, TRX1 or the empty vector
as negative control. As shown in Figure 10a, GRX1 and
TRX1 expression levels were significantly increased after
transfection.
Then, cells were incubated with 10 mM Ab(1–42) for 24 h
and cell viability was determined. Treatment with Ab(1–42)
(10 mM) decreased MTT reduction by approximately 40% in all
the experiments with nontransfected and vector-transfected
cells (Po0.001) (Figures 10b–d). Overexpression of TRX1
completely protected cells from Ab(1–42) toxicity (Figure
10b). Overexpression of GRX1 also protected cells against
Ab(1–42) toxicity (Po0.001) but not to the same extent as
seen with TRX1. Ab(1–42) treatment in GRX1-transfected
cells still decreased MTT reduction to approximately 80%, a
level that was significantly different to both nontransfected
and vector-transfected cells (Po0.05) (Figure 10c). Transfec-
tion of cells with empty vector had no effect on Ab(1–42)
toxicity (Figure 10d).
Discussion
Oxidative stress is believed to have an early role in AD
pathology and several reports have suggested that endogen-
ous antioxidant systems could be affected in the disease.19,20
The GRX1 and TRX1 endogenous antioxidant systems are
key players in maintaining the cellular redox status.6 In
addition to their role as antioxidants, both GRX1 and TRX1
have been shown to regulate apoptosis. Reduced GRX1 and
TRX1 are able to bind to ASK1 and inhibit the proapoptotic
MAPK cascade that leads to the activation of JNK, p38 and to
the cytosolic translocation of Daxx.7,8 It is well known that Ab
triggers the production of ROS, inducing neuronal cell death
(reviewed in Small et al.3). Very recently Kadowaki et al.12
demonstrated that activation of ASK1 was a key event in Ab
toxicity. Despite their importance as regulators of oxidative
stress and apoptosis, the role of GRX1 and TRX1 in AD is
largely unknown. To provide insight of GRX1 and TRX1 in the
context of AD, we addressed the roles of GRX1 and TRX1 in
the mechanisms of Ab neurotoxicity and how GRX1 and TRX1
levels are affected in AD.
We found that GRX1 levels were increased in some
neurons in both frontal cortex and hippocampal CA1 regions
of AD brains. In contrast, we found a reduction of neuronal
TRX1 levels in the same regions. This is the first study
showing expression levels of GRX1 in AD brain. Two previous
reports studied TRX1 in AD. Lovell et al.11 reported a general
decrease of TRX1 from several regions in AD brains. This is in
apparent agreement with our study, although it was made in
Figure 9 IGF-I protects against Ab toxicity in a PI3K-independent manner. (a)
Immunoblotting for phospho-Akt or phospho-ERK in SH-SY5Y cells after the
following treatments: untreated, Ab(1–42) (10 mM), IGF-I (20 nM), coincubation
of IGF-I (20 nM) with Ab(1–42) (10 mM) without and with the specific inhibitors
LY294002 (50 mM; for PI3K) and U0126 (5mM; for MEK/ERK). The inhibitors
were used in a 30 min pretreatment and during the incubations with the different
conditions for 2 and 5 h. (b) Effects of IGF-I (20 nM) on Ab(1–42) (10 mM)
induced decrease of cell viability. C¼ untreated cells; Ab¼ Ab(1–42) (10 mM,
5 h); Ab þ IGF-I¼ coincubation of Ab(1–42) (10 mM) and IGF-I (20 nM) for 5 h;
LY¼ LY294002 (50 mM); U0¼U0126 (5 mM). Inhibitors LY and UO were used
in a 30 min pretreatment and during the coincubations with Ab(1–42) and IGF-I.
Data are expressed as percentage of values for untreated cells and represent the
mean7S.E.M of three experiments performed in triplicate (*Po0.05;
***Po0.001 against untreated cells. zzPo0.01; zzzPo0.001 versus Ab-
treated cells. #Po0.05; ###Po0.001 versus Abþ IGF-I-treated cells; ANOVA
followed by Fisher’s PLSD post hoc test)
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brain homogenates containing both neuronal and glial TRX1.
In an earlier report, Asahina et al.14 saw an increase of TRX1
levels in astrocytes in AD brains as compared to healthy
controls. In contrast with our study and with the observations
of others,21 no staining in neurons was reported in this article.
However, as discussed in the results section, an increased
TRX1 immunoreactivity in AD glial cells would further confirm
the hypothesis that differences in neuronal TRX1 are masked
when brain homogenates are analyzed.
The expressions of both GRX1 and TRX1 have been
reported to be induced by various types of oxidative stress
(for a review, see Grant 22). However, a decrease in TRX1
levels has previously been shown to occur in some diseases
involving oxidative conditions, such as in neurons from
spontaneously hypertensive rats.23 The fact that TRX1 also
modulates a number of transcription factors24 and stress-
signaling kinases, like ASK125 involved in apoptosis, suggests
that a decrease of TRX1 may contribute to the neurodegene-
rative mechanisms of AD. On the other hand, the simulta-
neous increase of GRX1 in neurons of AD brains may also be
of importance. The fact that those neurons overexpressing
GRX1 showed an apparent normal morphology suggests
that they could possibly have a better protection against
the neurodegenerative events occurring in AD. In accor-
dance with this idea, a previous report has shown that in
tangle-bearing hippocampal CA1 neurons, GRX1 mRNA
levels were reduced six times as compared to normal neurons
in AD brains.
The upregulation of GRX1 seen in AD brain could be a
compensatory effect to counteract the reduction of TRX1. An
inverse relation between Grx1 and Trx1 expression has
been demonstrated in Escherichia coli, where Grx1 levels
are increased in bacteria lacking Trx1 and vice versa.26 In
addition, a functional link between Grx and Trx expressions
has also been described in yeast, where a lack of Trx causes a
decrease in GSH levels, which are compensated for by an
increased Grx expression.27 A reduction of GSH levels has
been previously demonstrated in AD brain,28 suggesting the
possibility of a similar mechanism.
We treated human SH-SY5Y neuroblastoma cells with
different Ab species and examined the redox status of GRX1
and TRX1. Ab is a key molecule in AD pathology and has been
shown to be neurotoxic by different mechanisms including the
induction of oxidative stress (for a review, see Small et al.3).
We found that Ab(1–42) caused a strong and early oxida-
tion of both GRX1 and TRX1 that was transient with time. The
intensity and early nature of these effects were in contrast
with those seen for other antioxidant systems. We showed
that catalase activity was increased at 5 and 24 h and levels of
GSH were decreased after 24 h in response to Ab(1–42)
treatment. Our results suggest that GRX1 and TRX1 are in
the first line of response against the oxidative stress caused
by Ab(1–42), at least in SH-SY5Y neuroblastoma cells. As
previously discussed, the reduction in GSH levels is in
accordance with earlier reports from studies with AD brain28
and also with other in vitro studies.29 The decrease in GSH
levels could further suggest that glutathione participates in the
recuperation of reduced GRX1 seen at 24 h (see Figure 1). On
the other hand, the recuperation of reduced TRX1, seen at
24 h, could indicate an additional upregulation of the reducing
Figure 10 Overexpression of GRX1 or TRX1 protects cells from Ab toxicity. (a) Immunoblotting of GRX1 or TRX1 expression in nontransfected (NT), pIRES vector
(VT), pIRES/GRX1 (GRX1T) and pIRES/TRX1 (TRX1T) transiently transfected human SH-SY5Y neuroblastoma cells. Effects of Ab(1–42) (10 mM, 24 h) on cell viability
in (b) GRX1-transfected, (c) TRX1-transfected and (d) vector-transfected cells. Data represent the mean values from seven to nine wells7S.E.M. and are expressed as
percentage of values for untreated cells in the respective experiments. (*Po0.05 ***Po0.001 versus untreated cells; ###Po0.001 versus Ab(1–42)-treated cells;
ANOVA followed by Fisher’s PLSD post hoc test)
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mechanisms of TRX1, that is, TRXR. In agreement with this
idea TRXR levels have been shown to be increased in AD.11
Several reports have shown that Ab induces apoptosis in a
number of different models (for a review, see Small et al.3). On
the other hand, both GRX1 and TRX1 have been shown to be
negative regulators of ASK1, a stress-activated and apopto-
tic-inducing kinase. This negative regulation of apoptosis is
dependent on the redox state of GRX1 and TRX1. ASK1 is
bound to the reduced form of GRX1 and TRX1, but when
GRX1 and TRX1 are oxidized ASK1 is free and can initiate
apoptosis.7 In view of this, we hypothesized that the strong
and quick oxidation of GRX1 and TRX1 by Ab, albeit transient,
could participate in the mechanism by which Ab is proapopto-
tic, by liberating ASK1. Indeed, we first showed that Ab(1–42)
decreased cell viability and induced apoptosis in our
paradigm. We then demonstrated the involvement of the
ASK1 cascade by showing that Ab induced cytosolic
translocation of Daxx at 2, 5 and 24 h treatment. Daxx is a
downstream protein in the ASK1 pathway located in the
nucleus under normal conditions. However, under oxidative
stress, ASK1 activates JNK, which phosphorylates Daxx
and uncovers a nuclear export signal leading to translocation
of Daxx to the cytoplasmic compartment.9 It has also been
observed that Daxx is involved in the activation of ASK1.30 In
concordance with our finding that Ab induced cytosolic
translocation of Daxx, Kadowaki et al.12 showed that ASK1
is activated by Ab in PC12 cells, and that ASK1 is in fact
necessary for Ab toxicity. In primary neuronal cultures derived
from E14.5 ASK/ mice, JNK activation by Ab was excluded
and cell viability was almost four-fold compared to ASKþ /þ
cells. Also, others have shown that ASK1 is required for
oxidative stress-induced activation of JNK, a downstream
kinase of ASK1,31 and that ASK1 is critical for Ab toxicity in
SH-SY5Y cells.18 This evidence together with our results
strongly suggests that activation of ASK1 is a key mechanism
for Ab neurotoxicity. Furthermore, since GRX1 and TRX1
when oxidized no longer bind to ASK1 leading to its activation,
it is also suggested that the strong and early oxidation of
GRX1 and TRX1 by Ab could participate in this mechanism.
To further investigate this hypothesis, we next analyzed
possible strategies of protection against Ab toxicity based on
inhibiting ASK1 and on overexpressing GRX1 or TRX1.
Previous studies have shown that IGF-I protects cells from
Ab toxicity. This protection has been shown to involve both
activation of ERK and PI3K signaling pathways by IGF-I.18 In
a recent work, Galvan et al.17 demonstrated that IGF-I
treatment inhibits the ASK1 activation seen in serum-starved
L929 cells independently of the PI3K pathway. Others have
also shown that ASK1 can be inhibited by Akt, a serine/
threonine kinase that is activated by PI3K.32 In view of this, we
analyzed the ability of IGF-I to protect against Ab(1–42) in our
model when PI3K and/or ERK pathways were blocked with
the specific inhibitors LY294002 and U0126, respectively. We
showed that IGF-I completely protected against Ab(1–42)-
induced cell death. In accordance with Galvan et al.,17
inhibition of PI3K did not have a strong effect on the IGF-I
protection against Ab toxicity. IGF-I was not protective when
the MEK/ERK or both PI3K/Akt and MEK/ERK pathways were
inhibited. These results provide supplementary evidence that
ASK1 activation is a likely important component of the
mechanism of Ab toxicity and that this toxicity may be
prevented by pharmacological inhibition of ASK1.
Our results from brain tissue indicate that increased
levels of GRX1 could be protective. Finally, we explored the
possibility that increased levels of GRX1 or TRX1 protect SH-
SY5Y cells from Ab toxicity. A number of reports have shown
that raised levels of GRX or TRX by exogenous recombinant
administration or by overexpression protect cells against
several insults.10,33,34 Here, we showed that increasing levels
of GRX1 or TRX1 by transient transfection protect against
Ab(1–42) toxicity in SH-SY5Y cells. Taking these results
together with those seen in AD brains, an increase of GRX1
in healthy neurons and the general decrease of TRX1, it is
suggested that increased brain levels of GRX1 and TRX1
could be beneficial for counteracting Ab toxicity and possibly
also the progression of AD pathogenesis.
In summary, we demonstrate that in AD brains, GRX1
levels are increased in neurons without signs of degeneration,
while neuronal TRX1 levels are generally decreased. We
also demonstrate that Ab(1–42) caused an early, strong and
transient oxidation of both GRX1 and TRX1, and induced
apoptosis by activation of the ASK1 cascade in SH-SY5Y
cells. We show that pharmacological inhibition of ASK1 by
IGF-I as well as overexpression of GRX1 or TRX1 protect
cells against Ab(1–42) toxicity. In view of this, we propose
a model (Figure 11) by which Ab toxicity could occur primarily
by causing oxidative stress. The GRX1 and TRX1 endo-
genous antioxidant systems are in the first line of defense to
try to maintain the cellular redox homeostasis. However,
GRX1 and TRX1 oxidations cause the liberation and activa-
tion of ASK1 and subsequent initiation of apoptosis.
Our results strongly suggest that deregulation of GRX1 and
TRX1 antioxidant systems could be important in the patho-
genesis of AD. Moreover, strategies leading to inhibition of
Figure 11 Schematic representation of the involvement of GRX1 and TRX1 on
Ab(1–42) toxicity. Oxidative stress caused by Ab induces a strong early oxidation
of GRX1 and TRX1. As a consequence, the inhibitory binding of GRX1 and TRX1
to ASK1 is disrupted and ASK1 is liberated and initiates an apoptosis cascade.
Treatment with IGF-I or overexpression of GRX1 or TRX1 inhibits ASK1 and
protects cells against the Ab toxicity
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ASK1 or to an increase of GRX1 or TRX1 in neurons may
have therapeutic applications for the treatment of this disease.
Materials and Methods
Materials
Ab(25–35) and Ab(35–25) were purchased from Sigma-Aldrich (Stock-
holm, Sweden). Ab(1–42) was from US Peptide (Rancho Cucamonga,
CA, USA) and dissolved in serum-free minimum essential medium (MEM).
Before use, the Ab was incubated at 371C with sporadic shaking for
48 h.35 Others have shown that similar preparations of Ab(1–42) contain
Ab fibrils along with protofibrils and stable oligomers.36
AMS was from Molecular Probes (Leiden, The Netherlands). Catalase,
Purpald, trichloroacetic acid (TCA), okadaic acid, phenylmethylsulfonyl
fluoride (PMSF), leupeptin, aprotinin, IGF-I and thiazolyl blue tetrazolium
bromide (MTT-salt) were from Sigma-Aldrich (Stockholm, Sweden).
Potassium periodate was purchased from Scharlau Chemie (Barcelona,
Spain). LY294002 was from Calbiochem (La Jolla, CA, USA). U0126 was
from Cell Signaling Technology (Beverly, MA, USA). All other chemicals
were standard laboratory reagents.
Brain samples and tissue preparation
Post-mortem brain material was obtained from the Huddinge Brain Bank
(Karolinska University Hospital, Sweden) with approval by the Human
Ethics Committee of Karolinska University Hospital. Four definite AD
brains (two males, 79 and 89 years old; two females, 76 and 80 years old)
and three age-matched control (two males, 66 and 83 years old; one
85-year-old female) were used for immunohistochemistry. All brains had a
post-mortem delay between 24 and 48 h. For immunoblotting, samples
from temporal cortex from six AD brains (two males and four females,
8479 years old) and four controls (four males, 6677 years old)
were used. The brains had a post-mortem delay between 8 and 34 h. The
AD cases met the clinical diagnosis of probable AD (Diagnostic and
Statistical Manual of Mental Disorders-IV, DSM-IV criteria) as well as
definite AD after Consortium to establish a Registry for Alzheimer’s
disease (CERAD) neuropathological criteria.37
Brain samples intended for immunocytochemistry were fixed in buffered
4% formaldehyde and embedded in paraffin. For immunoblotting, brain
samples were sonicated 4 15 s in a buffer consisting of 40 mM Tris-HCl
(pH 6.8) and 2% SDS, with freshly added protease inhibitor cocktail
(Sigma-Aldrich, Saint Louis, MO, USA) at a dilution of 1 : 500 and
phosphatase inhibitors (20 mM b-glycerophosphate, 2 nM okadaic acid,
50 mM sodium flouride, 1 mM sodium orthovanadate).
Immunohistochemical analysis
Sections (7 mm thick) were mounted onto Superfrost plus-glass (Menzel
Braunschweig, Germany), baked at 371C overnight, dewaxed and
hydrated. Then, sections were blocked for nonspecific sites with Dako-
protein block (X0909) (Dako, Cytomation, Denmark) for 30 min prior to
incubations over night at 41C with primary antibodies (anti-GRX1 or anti-
TRX1). Then, sections were incubated for 30 min with secondary antibody
diluted in TBS, followed by incubation in ABC-Elite HRP (Vector
laboratories Burlingame, UK) for 1 h. Reactions were visualized by
developing the sections in Dab (Sigma-Aldrich, Sweden). The sections
were thoroughly washed in TBS between different steps. Finally, the
sections were dehydrated and mounted in DPX (BDH, Poole, UK). The
protocol for antibodies was repeated to assure the reproducibility of
results. All sections were treated simultaneously under the same
conditions. For control staining, the primary antibody was omitted. For




Stereological semiquantification was performed as previously described.38
The regions used were dorsal frontal cortex pyramidal layer III, CA1 region
of hippocampus and granular cell layer of dentate. A computer-generated
counting frame was superimposed on the screen of a CAST–GRID 1.2
software program (Olympus, Denmark). Three slides per brain were
examined. According to the intensity of the neuronal staining, the
cells were divided in two groups: heavily stained cells and low or
nonstained cells.
Cell culture
Human neuroblastoma SH-SY5Y cells were cultured in MEM with Earle’s
salts and L-alanine and L-glutamine, supplemented with 10% fetal bovine
serum (FBS), 100 U/ml penicillin, 100 mg/ml streptomycin at 371C in a
humidified atmosphere of 5% (v/v) CO2/air. All cell culture supplies were
purchased from Gibco Invitrogen Corporation (European division, Ta¨by,
Sweden). Before treatments, cells were washed with serum-free MEM. All
treatments were used under serum-free conditions. Untreated cells were
used as controls.
Redox state assessment
Cells were treated with Ab(25–35) (10 mM), Ab(35–25) (10 mM) or
Ab(1–42) (10 mM) in MEM medium (pH 7.4) under serum-free conditions,
for 1, 5 or 24 h. Untreated cells were used as controls. After treatment,
cells were washed with ice-cold phosphate-buffered saline (PBS). To
quench further disulfide exchange and preserve the post-treatment cellular
oxidation state, the cells were rapidly treated with 20% (w/v) trichloroacetic
acid (TCA).39 Cells were harvested and collected by centrifugation
(2000 g for 10 min) at þ 41C. TCA-treated pellets were washed twice
with 70% acetone and resuspended in sample buffer (62.5 mM Tris-HCl
pH 7.5, 2% SDS, 10% glycerol, 0.001% bromophenol blue) with freshly
added protease inhibitors (50 mg/ml PMSF, 20mg/ml leupeptin, 20mg/ml
aprotinin). In order to dissolve the TCA precipitates completely, the
samples were sonicated. Samples were stored frozen at 801C prior to
immunoblotting. Samples were boiled for 3 min at 951C prior to incubation
with the thiol-specific probe AMS overnight at room temperature. AMS
covalently modifies the reduced form of the proteins, which markedly
retards electrophoretic migration of proteins in SDS-PAGE and gives an
unequivocal separation of oxidized and reduced forms of the proteins.39
Protein concentrations were determined using the bicinchoninic acid
(BCA) protein assay kit (Pierce, Rockford, IL, USA). Equivalent amounts of
protein were separated by SDS-PAGE using 15 or 18% acrylamide gels.
Immunoblotting
Immunoblotting was performed as previously described.35 Table 2
shows the different primary antibodies used. Some of the immunoblots
were stripped using stripping buffer (62.5 mM Tris-HCl, pH 6.7, 2% SDS,
100 mM mercaptoethanol) at þ 501C for 30 min, and then reblotted.
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For the experiments including IGF-I, cells were either left untreated
or treated with 50mM LY294002 and/or 5 mM U0126 for 30 min prior and
during cotreatment with 10mM Ab(1–42) and 20 nM IGF-I for 5 h. Cells
were then washed with PBS, harvested, and collected by centrifugation at
þ 41C (2000 g, 10 min). Cells were lysed with lysis buffer (20 mM Tris-
HCl pH 7.4, 137 mM NaCl, 2 mM EDTA, 2% NP-40, 2% Triton X-100) with
freshly added protease inhibitor cocktail (Sigma-Aldrich, Saint Louis,
MO, USA) at a dilution of 1 : 500 and phosphatase inhibitors (20 mM
b-glycerophosphate, 2 nM okadaic acid, 50 mM sodium flouride, 1 mM
sodium orthovanadate). Lysates were stored frozen at 801C.
Determination of catalase activity
Catalase activity was determined as described elsewhere.40 Cells
were grown in 6 cm2 polystyrene plates. After treatment, the cells were
washed with ice-cold PBS, harvested and collected by centrifugation
at þ 41C (2000 g for 10 min). Pellets were suspended in 50 mM
K3PO4 pH 7.0, 1 mM EDTA buffer and sonicated. The cell lysates were
centrifuged again at þ 41C (10 000 g for 15 min) and supernatants
were saved and stored frozen at 801C prior to analyses. The assay
utilizes the peroxidatic activity of catalase to transform methanol and H2O2
into formaldehyde. The chromagen Purpald was used to visualize the
formation of formaldehyde, by measuring the absorbance at 550 nm in a
plate reader spectrophotometer (Molecular Devices Spectra MAX 250).
The analysis was performed in 96-well plates using formaldehyde as
standard (0–75 mM). Care was taken during the whole sample preparation
not to overheat cell lysates, since this can inactivate catalase.
Measurement of reduced glutathione levels
A GSH detection kit (Chemicon, Temecula, CA, USA) was used according
to the manufacturer’s protocol to detect GSH levels. This kit uses the
dye monochlorobimane (MCB) that has a high affinity for GSH.
When unbound, MCB is almost nonfluorescent, whereas GSH-bound
dye fluoresces blue. Fluorescence was measured by a FLUOstar
Galaxy multiwell plate reader (BMG Labtechnologies GmbH, Offenburg,
Germany), the excitation and emission wavelengths being 380 and
460 nm, respectively.
Cell viability and apoptosis measurements
Cell viability was assessed by a modified version of the MTT assay that
depends on the reduction of the tetrazolium salt MTT to formazan by living
cells.35 Cells were cultured in 24-well plates and treated for the indicated
time points with 10mM Ab(1–42). For the experiments including IGF-I,
medium was changed to serum-free MEM and the cells were either left
untreated or treated with 50 mM LY294002 and/or 5 mM U0126 for 30 min
prior and during cotreatment with 10 mM Ab(1–42) and 20 nM IGF-I for 5 h.
After treatment, a MTT solution (0.3 mg/ml) made in serum-free MEM
without phenol red was added to the cells. After 1 h incubation at 371C, the
MTT solution was aspirated and isopropanol was added to the cells.
Aliquots were transferred to a 96-well plate and absorbances measured at
540 nm in a plate reader spectrophotometer (Molecular Devices Spectra
MAX 250). Results were expressed as percentages of the respective value
obtained for untreated cells at each time point.
Detection of apoptotic mono- and oligo-nucleosomes was performed
using the Cell Death Detection ELISAPLUS kit (Roche Diagnostics
Scandinavia AB, Bromma, Sweden) according to the manufacturer’s
instructions. The assay is based on a quantitative sandwich ELISA using
mouse monoclonal antibodies directed against DNA and histones,
respectively. This renders the in vitro determination of apoptosis-
characteristic mono- and oligo-nucleosomes possible. The assay was
performed in 96-well plates, measured spectrophotometrically at 405 nm
(Molecular Devices Spectra MAX 250).
Immunocytochemistry
Cells grown on chamber slides were fixed in methanol for 30 min on ice.
Nonspecific binding of antibodies was blocked by addition of 10% BSA in
TBS-t for 30 min. Cells were incubated with primary antibody (Table 2)
Table 2 Summary of antibodies and working conditions used in the experiments





Anti-actin Rabbit, polyclonal Sigma-Aldrich, St. Louis, MO, USA 1 : 1000 Overnight, +41
Anti-phospho Akt
(Ser 473)
Rabbit, polyclonal Cell Signaling Technology, Beverly, MA, USA 1 : 1000 Overnight, +41
Anti-Daxx Mouse, monoclonal MBL Int. Corp., Woburn, MA, USA 1 : 100c, 1 : 1000a 1 h, room temp.
Anti-phospho ERK Rabbit, polyclonal Cell Signaling Technology, Beverly, MA, USA 1 : 1000 Overnight, +41
Anti-GFAP Mouse, monoclonal BD Biosciences Erembodegem, Belgium 1 : 1000 Overnight, room temp.
Anti-GRX1 Goat, polyclonal IMCO Corp., Stockholm, Sweden 1 : 1000 Overnight, room temp.
Anti-Lamin A Rabbit, polyclonal Cell Signaling Technology, Beverly, MA, USA 1 : 1000 Overnight, +41
Anti-Synaptophysin Mouse, monoclonal DAKO Cytomation, Glostrup, Denmark 1 : 1000 2 h, room temp.
Anti-TRX1 Goat, polyclonal IMCO Corp., Stockholm, Sweden 1 : 1000 Overnight, room temp.
Secondary antibodies
Anti-goat IgGa (HRP) Horse Vector Laboratories, Burlingame, CA, USA 1 : 1000 1 h, room temp.
Anti-goat IgGb
(Biotin)
Rabbit DAKO Cytomation, Glostrup, Denmark 5mg/ml 1 h, room temp.
Anti-mouse IgGa
(HRP)
Sheep Amersham Biosciences, Little Chalfont, England 1 : 2000 1 h, room temp.
Anti-mouse IgGc
(Alexa Fluor 488)
Goat Molecular Probes, Leiden, The Netherlands 1 : 1000 1 h, room temp.
Anti-rabbit IgGa
(HRP)
Donkey Amersham Biosciences, Little Chalfont, England 1 : 2000 1 h, room temp.
aImmunoblotting. bImmunohistochemistry. cImmunofluorescence
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diluted in TBS-t with 3% BSA. Cells were rinsed in TBS-t (3 10 min)
before incubation with secondary antibody in TBS-t with 3% BSA for 1 h in
the dark. Finally, cells were rinsed in TBS-t (3 10 min) and mounted in
fluorescence mounting medium (DAKO Cytomation, Glostrup, Denmark).
Nikon Eclipse E800 microscope and Nikon FDX35 camera were used
when analyzing the result of the immunocytochemistry.
Subcellular fractionation
Nuclear and cytosolic fractions of cells were isolated using the nuclear and
cytoplasmic extraction reagents kit NE-PER (Pierce, Rockford, IL, USA),
according to the manufacturer’s protocol. Protease inhibitor cocktail
(Sigma-Aldrich, Saint Louis, MO, USA) was added freshly at a dilution of
1 : 500. Purity of fractions was assessed by immunoblotting with anti-
Lamin-A antibody, a nuclear membrane protein used as specific nuclear
marker. Densitometric analysis of immunoreactive bands on immunoblots
was performed by multiplying the optical density and the area of the
selected band, obtained through NIH Image 1.63 software.
DNA constructs and transfections
The mutagenic forward primers 50-CGAATTCGCCACCATGGATTACAAG
GATGACGACGATAAGGCTCAAGAGTTTGTGAAC-30 for GRX1 and 50-
CGAATTCGCCACCATGGATTACAAGGATGACGACGATAAGATGGTG
AAGCAGATCGAG-30 for TRX1, and the reverse primers 50-CGGATCCTT
ACTGCAGAGCTCCAATC-30 for GRX1 and 50-CGGATCCTTAGACTAAT
TCATTAAT-30 for TRX1 were used to amplify the respective open
reading frames (ORF) by PCR from human testis Marathon-readyt cDNA
(Clontech, Heidelberg, Germany). The forward primers introduced
an EcoRI site followed by a Kozac sequence preceding the Flag epitope
sequence and the corresponding GRX1 or TRX1 sequences. The reverse
primers introduced a BamHI site after the GRX1 or TRX1 stop
codons. The amplified DNA was cloned into the EcoRI–BamHI sites of
the pIRESneo expression vector (Clontech, Heidelberg, Germany) and the
resulting plasmids pIRES/GRX1 and pIRES/TRX1 were transformed
into E. coli TOP-10 F0 strain. The final constructs were purified using
the midi-prep kit (QIAGEN Sciences, Maryland, USA) and confirmed
by DNA sequencing.
Transient transfections were performed in 12-well plates using
Lipofectaminet 2000 (Gibco Invitrogen Corporation; European division,
Ta¨by, Sweden) according to the manufacturer’s instructions. SH-SY5Y
cells were cultured until 90% confluence in 12-well plates and transfected
with 0.8mg of DNA. Cells were incubated for 24 h before changing media
for serum-free MEM with or without 10 mM Ab(1–42) and cells were
treated for 24 h prior to measuring cell viability.
Statistical analyses
Analyses of differences were carried out by Student’s t-test or by ANOVA
followed by Fisher’s PLSD post hoc test. A value of Po0.05 was
considered statistically significant.
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